Study of strategy for secondary failure of infliximab maintenance therapy to measure anti-infliximab antibody levels in patients with inflammatory bowel disease.

Study of strategy for secondary failure of infliximab maintenance therapy to measure anti-infliximab antibody levels in patients with inflammatory bowel disease. - IFXATIIBD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026171

Enrollment

150

Registered

2017-02-17

Start date

2017-02-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: It is the patient receiving anti-TNF-alpha antibody preparation (infliximab (Remicade), adalimumab (Humira)) among patients with ulcerative colitis, bowel type Behcet's disease and Crohn's disease.

Exclusion criteria

Exclusion criteria: The patients that it was not obtained consent after explanation.

Design outcomes

Primary

Measure	Time frame
Two kinds evade that the second becomes invalid together early by doing the criteria for selection of anti-TNF-alpha antibody preparation having only two kinds if clear, and symptom exacerbation prevention of patients is enabled now.	—

Countries

Japan

Contacts

Public ContactHirotsugu Imaeda

Shiga University of Medical Science Division of Gastroenterology, Department of Medicine

imaeda@belle.shiga-med.ac.jp0775482217

Outcome results